Ibrutinib is a covalent inhibitor of Bruton’s tyrosine kinase (BTK), which is a crucial player in the development of mantle cell lymphoma (MCL) and is significantly upregulated in MCL cells. This evidence concerns the gene BTK and mantle cell lymphoma.